172 related articles for article (PubMed ID: 30822684)
1. A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma.
Herd F; Basta NO; McNally RJQ; Tweddle DA
Eur J Cancer; 2019 Apr; 111():50-58. PubMed ID: 30822684
[TBL] [Abstract][Full Text] [Related]
2. Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review.
Żebrowska U; Balwierz W; Wechowski J; Wieczorek A
Target Oncol; 2024 Mar; 19(2):143-159. PubMed ID: 38401028
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
[TBL] [Abstract][Full Text] [Related]
5. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
Moreno L; Rubie H; Varo A; Le Deley MC; Amoroso L; Chevance A; Garaventa A; Gambart M; Bautista F; Valteau-Couanet D; Geoerger B; Vassal G; Paoletti X; Pearson AD
Pediatr Blood Cancer; 2017 Jan; 64(1):25-31. PubMed ID: 27555472
[TBL] [Abstract][Full Text] [Related]
6. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2010 May; (5):CD006301. PubMed ID: 20464740
[TBL] [Abstract][Full Text] [Related]
7. Improved Outcomes with Induction Chemotherapy Combined with Arsenic Trioxide in Stage 4 Neuroblastoma: A Case Series.
Li Y; Feng C; Chen Y; Huang K; Li C; Xiong X; Li P; Zhou D; Peng X; Weng W; Deng X; Wu Y; Fang J
Technol Cancer Res Treat; 2021; 20():15330338211041454. PubMed ID: 34569870
[No Abstract] [Full Text] [Related]
8. The degree of tumor volume reduction during the early phase of induction chemotherapy is an independent prognostic factor in patients with high-risk neuroblastoma.
Yoo SY; Kim JS; Sung KW; Jeon TY; Choi JY; Moon SH; Son MH; Lee SH; Yoo KH; Koo HH
Cancer; 2013 Feb; 119(3):656-64. PubMed ID: 22952047
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.
Moreno L; Weston R; Owens C; Valteau-Couanet D; Gambart M; Castel V; Zwaan CM; Nysom K; Gerber N; Castellano A; Laureys G; Ladenstein R; Rössler J; Makin G; Murphy D; Morland B; Vaidya S; Thebaud E; van Eijkelenburg N; Tweddle DA; Barone G; Tandonnet J; Corradini N; Chastagner P; Paillard C; Bautista FJ; Gallego Melcon S; De Wilde B; Marshall L; Gray J; Burchill SA; Schleiermacher G; Chesler L; Peet A; Leach MO; McHugh K; Hayes R; Jerome N; Caron H; Laidler J; Fenwick N; Holt G; Moroz V; Kearns P; Gates S; Pearson ADJ; Wheatley K;
J Clin Oncol; 2024 Apr; 42(10):1135-1145. PubMed ID: 38190578
[TBL] [Abstract][Full Text] [Related]
10. Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma.
Polishchuk AL; Li R; Hill-Kayser C; Little A; Hawkins RA; Hamilton J; Lau M; Tran HC; Strahlendorf C; Lemons RS; Weinberg V; Matthay KK; DuBois SG; Marcus KJ; Bagatell R; Haas-Kogan DA
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):839-45. PubMed ID: 24867534
[TBL] [Abstract][Full Text] [Related]
11. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.
Kraal KC; Bleeker GM; van Eck-Smit BL; van Eijkelenburg NK; Berthold F; van Noesel MM; Caron HN; Tytgat GA
Eur J Cancer; 2017 May; 76():188-196. PubMed ID: 28329731
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.
Di Giannatale A; Dias-Gastellier N; Devos A; Mc Hugh K; Boubaker A; Courbon F; Verschuur A; Ducassoul S; Malekzadeh K; Casanova M; Amoroso L; Chastagner P; Zwaan CM; Munzer C; Aerts I; Landman-Parker J; Riccardi R; Le Deley MC; Geoerger B; Rubie H
Eur J Cancer; 2014 Jan; 50(1):170-7. PubMed ID: 24021349
[TBL] [Abstract][Full Text] [Related]
13. Re-induction chemotherapy regimens in patients with recurrent central nervous system mixed malignant germ cell tumors.
Abu Arja MH; Stanek JR; Finlay JL; AbdelBaki MS
Childs Nerv Syst; 2018 Nov; 34(11):2179-2186. PubMed ID: 30076436
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study.
Rujkijyanont P; Photia A; Traivaree C; Monsereenusorn C; Anurathapan U; Seksarn P; Sosothikul D; Techavichit P; Sanpakit K; Phuakpet K; Wiangnon S; Chotsampancharoen T; Chainansamit SO; Kanjanapongkul S; Meekaewkunchorn A; Hongeng S
BMC Cancer; 2019 Oct; 19(1):961. PubMed ID: 31619207
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.
Mody R; Zhao L; Yanik GA; Opipari V
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28436582
[TBL] [Abstract][Full Text] [Related]
16. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
[TBL] [Abstract][Full Text] [Related]
17. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
Rancea M; Monsef I; von Tresckow B; Engert A; Skoetz N
Cochrane Database Syst Rev; 2013 Jun; (6):CD009411. PubMed ID: 23784872
[TBL] [Abstract][Full Text] [Related]
18. A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.
Lewis EC; Kraveka JM; Ferguson W; Eslin D; Brown VI; Bergendahl G; Roberts W; Wada RK; Oesterheld J; Mitchell D; Foley J; Zage P; Rawwas J; Rich M; Lorenzi E; Broglio K; Berry D; Saulnier Sholler GL
Int J Cancer; 2020 Dec; 147(11):3152-3159. PubMed ID: 32391579
[TBL] [Abstract][Full Text] [Related]
19. Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk Neuroblastoma.
Schrey D; Vaidya SJ; Levine D; Pearson AD; Moreno L
J Pediatr Hematol Oncol; 2015 Apr; 37(3):e150-3. PubMed ID: 26201036
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.
Kraveka JM; Lewis EC; Bergendahl G; Ferguson W; Oesterheld J; Kim E; Nagulapally AB; Dykema KJ; Brown VI; Roberts WD; Mitchell D; Eslin D; Hanson D; Isakoff MS; Wada RK; Harrod VL; Rawwas J; Hanna G; Hendricks WPD; Byron SA; Snuderl M; Serrano J; Trent JM; Saulnier Sholler GL
Cancer Rep (Hoboken); 2022 Nov; 5(11):e1616. PubMed ID: 35355452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
